[Administration of levamisole to children with kidney disease exacerbation caused by recurrent respiratory infections].
Levamisole (2.1-3.1 mg/kg twice a week) was administered to 6 children aged between 20 months and 6.5 years for 1 to 4 months. All children suffered form the renal diseases exacerbation (nephrotic syndrome and pyelonephritis--2 children, lipoid nephrosis and pyelonephritis--2 children, pyelonephritis with glomerular reactions--1 child, recurrent pyelonephritis--1 child) due to recurrent respiratory infections levamisole improved both clinical and biochemical parameters of renal disease. Subsequent respiratory infections were milder and less frequent. Transient decrease in thrombocyte count was seen in 4 children after 2-8 weeks of therapy with levamisole. An increase in AspAT and (or) AlAT was noted in 2 children after 1-2 months of therapy. Levamisole was withdrawn in 2 children after 30 days due to an increase in AspAT activity, prolongation of blood clotting time and thrombocytopenia.
Prandota
J
J
Kobylińska
J
J
Lipowska
K
K
D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007674:Kidney Diseases / Q000188:drug therapy* / Q000209:etiology; D007978:Levamisole / Q000009:adverse effects / Q000627:therapeutic use*; D010976:Platelet Count / Q000187:drug effects; D012008:Recurrence; D012141:Respiratory Tract Infections / Q000150:complications*
D007978:Levamisole; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase
Stosowanie lewamizolu u dzieci z zaostrzeniami chorób nerek spowodowanymi nawracajacymi zakazeniami dróg oddechowych.